Chongqing Hilan Pharmaceutical Co., Ltd. (hereinafter referred to as "Hilan Pharmaceutical") originated from the "Wu Shu Fang" in the 37th year of the Kangxi reign (AD 1698). The core trademark "Hilan" has been recognized as a famous trademark in China. The traditional Chinese medicine brand "Wu Shu Fang" is a certified Chinese national intangible cultural heritage, and the "Traditional Production Technique of Wu Shu Fang Plaster" is a cultural heritage of Chongqing. Hilan Pharmaceutical is a demonstration production base for intangible cultural heritage in Chongqing.

At present, Hilan Pharmaceutical has developed into a comprehensive pharmaceutical enterprise integrating research and development, production and sales, with total assets of 3 billion yuan. The company has been successively recognized as a national high-tech enterprise, a national intellectual property demonstration enterprise, a leading enterprise in the national biobased industry, a national key enterprise in agricultural industrialization, and a "national green factory" recognized by the Ministry of Industry and Information Technology of the People's Republic of China. It has also won the "Chongqing Enterprise Innovation Award"; and ranked 42nd in the 2024 China Pharmaceutical Market Pharmaceutical Enterprise List (Traditional Chinese Medicine).

The Hilan production base is located in the Industrial Park of Hechuan District, Chongqing City. It covers an area of 400 square meter and has 18 different dosage form production lines of traditional Chinese medicine, all of which have passed the compliance checks of the new version of GMP. The enterprise is vigorously promoting the construction of intelligent manufacturing, with a total investment of 1.2 billion yuan. It has built a digital production factory for Chinese patent medicines and established an intelligent manufacturing system centered on data-driven, achieving intelligent production processes and lean operation management. It has been awarded the title of "National Green Factory", "Chongqing Digital Workshop", and ranked as one of the top ten smart health factories in Chongqing in 2020.

The enterprise has implemented a comprehensive marketing strategy. Its sales network covers all provinces, autonomous regions and municipalities of China, forming a sales pattern that deeply penetrates from the comprehensive hospitals in provincial capitals to the county-level, township-level health centers, individual clinics, and retail pharmacies. It has established a product pipeline with competitive market advantages in fields such as orthopedics, dermatology, sleep, cardiovascular and cerebrovascular diseases, digestion, respiratory system, and tonic products.

The enterprise has a total of 101 varieties included in the "National Basic Medical Insurance Drug List", 31 varieties included in the "National Essential Medicines List", and 30 exclusive varieties. Some key varieties such as Musk Chasing-Air Pain Relief Ointment, Dadi Seven-Clear Tablets, and Jinchan Anti-itch Capsules are exclusive or patented products. They have received honors such as national or provincial science and technology progress awards, Chongqing Major New Products, and Chongqing High-tech Products.

Hilan Pharmaceutical adheres to the corporate mission of "Virtue Benefits the World, Medicine Relieves All Living", and takes "using technology to serve human health" as its innovation strategy. It has established a research pattern of "screening a batch, developing a batch, and storing a batch". Currently, the company has a national enterprise technology center, a postdoctoral research station in Chongqing, a Chongqing engineering technology research center for traditional Chinese medicine preparations, a Chongqing industrial and information technology key laboratory for traditional Chinese medicine rubber plasters, and a project for the construction of the research and development platform for Chinese medicinal materials processing and technology (Phase I).

The enterprise actively explores mechanisms for joint education, school-enterprise collaboration and industry-academia integration, jointly establishing the "Biomedical Collaborative Innovation Center", promoting technological exchanges and cooperation between universities, research institutes and enterprises, and facilitating the transformation of innovative achievements. The cooperating units include: China Academy of Chinese Medical Sciences, Academy of Military Medical Sciences AMS PLA, Beijing University of Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences, West China Medical center, Sichuan University, Army Medical University, Chengdu University of TCM, Chongqing Academy of Chinese Materia Medical.

As of now, the enterprise has obtained a total of 213 drug production licenses; it has cumulatively applied for 200 Chinese patents and holds 50 valid invention patents; it has formulated and revised 100 national standards; it has won 4 awards for scientific and technological progress in Chongqing; it has undertaken over 40 national and municipal-level scientific research projects; it has received 3 grants from the National Science and Technology Department's Small and Medium-sized Enterprise Innovation Fund, and participated in 3 major new drug creation projects; several products have been recognized as China's famous and superior brands, national key new products, Chongqing's well-known products, Chongqing's outstanding new products, Chongqing's key new products, Chongqing's major new products, and Chongqing's high-tech products.

The enterprise has vigorously implemented the "10050 Strategy", adhering to the modernization of traditional Chinese medicine as the core strategic path. It has vertically integrated the industrial chain and horizontally expanded business segments, building a large health ecosystem. Focusing on the three strategic resources of talents, technology and products, it strives to build organizational capabilities that support rapid growth. It inherits the essence of the "Wu Shufang" Chinese老字号， promotes traditional Chinese medicine culture， adheres to the bottom line， and operates in compliance with regulations.